GSK is close to buying Chinese-based specialist urology drugmaker Nanjing MeiRui Pharma according to various reports.
The deal, which was reported by Reuters and the Wall Street Journal and is expected to complete before the end of the year, would fit with the UK drug majors previously announced plan to grow in emerging markets through small scale purchases.
Speaking at the Reuters Health Summit earlier in the month GSK CSO David Redfern said he is examining small-scale acquisitions
Nanjing’s specialisation in urological conditions would also fit with GSK’s therapeutic focus, particularly its product Avodart which is the world’s best selling benign prostatic hyperplasia (BPH) treatment.
A GSK spokeswoman told in-Pharmatechnmologist that the UK firm does not comment on such speculation.